FDA approves Teligent’s gentamicin sulfate cream

Teligent has received the Food and Drug Administration’s clearance for gentamicin sulfate cream, 0.1% (gentamicin base). 

The product has a market value of roughly $15.6 million, according to IQVIA October data.

“This latest approval further demonstrates Teligent’s commitment to research and development and our ability to bring these drugs to market successfully,’’ Jason Grenfell-Gardner, president and CEO said.

The product is expected to be launched in November 2019.